Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female subjects, 18-65 years of age with a diagnosis of SPMS~* HLA DR2 and/or DR4 positive~* Absence of a relapse in the 3 months prior to baseline~* EDSS of 3.0 - 6.5~Exclusion Criteria:~* Therapy with Beta-interferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline~* Treatment with Tysabri within 2 years of baseline~* Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).